Amarex Taiwan Chief Operating Officer, Dr. Chia-Hua Maggie Ho, Featured in 2021 End-of-year Global Bio Investment Article: Bringing U.S. FDA Review Criteria to the Taiwanese Biotech Industry

​

Many non-COVID-19 global clinical trials are delayed or terminated early due to the COVID-19 pandemic. The clinical trials carried out by Amarex were not forced to be suspended or terminated during the pandemic. Amarex set up the monitoring plan and audit system remotely and that not only overcomes the difficulty of on-site monitoring but also ensures the quality of clinical trials and the safety and rights of subjects.

Amarex Taiwan Exhibiting at BIO Asia-Taiwan 2021 | Nov. 4-7 | Taipei, Taiwan

​

Taipei, Taiwan (November 02, 2021) – We are pleased to announce that Amarex Taiwan, LLC is exhibiting at BIO Asia-Taiwan 2021, held November 4-7 at the Taipei Nangang Exhibition Center in Taiwan.

Amarex Passes Taiwan FDA GTP Audit: Result is a Resounding No Findings

​

Taipei, Taiwan (September 16, 2021) – Amarex Taiwan, LLC announces a no findings result of a Taiwan Food and Drug Administration (TFDA) audit of its office last month.

Amarex Featured in 15-year Anniversary Issue of the NSF International Journal

​

The just released Issue 48 of NSF International’s Health Science Journal features contributions by Amarex Clinical Research, LLC. This journal is available at https://www.nsf.org/periodicals/health-sciences-journal/issue-48.